Sa Rang Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sa Rang Kim has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Michael Girardi
Department of Dermatology Yale School of Medicine New Haven Connecticut USA
4 shared publications - Francine M. Foss
Yale University School of Medicine
3 shared publications - Amber Loren Ong King
Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA
2 shared publications - Christine J. Ko
Department of Dermatology Yale School of Medicine New Haven Connecticut USA
2 shared publications - Fatima N. Mirza
Department of Dermatology, The Warren Alpert Medical School of Brown University, Providence, USA
2 shared publications - Julia M. Lewis
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Photochemistry and Photobiology
UV signature mutation hyperhotspots as genomic dosimeters
Screening for UV‐sensitive DNA mutation sites as dosimeters for individual sun exposure, using high‐fidelity Duplex Sequencing to reduce false positives and a stringent genome alignment protocol to reduce false negatives, revealed: (i) Sun‐exposed human skin contained UV signature mutations (C → T at a diypyrimidine) >1000‐fold more frequently than unexposed neonatal skin, making these mutations sensitive genomic dosimeters for UV exposure. (ii) Tumor suppressor gene hotspot nucleotides (nt) reached variant allele frequency (VAF) 0.1%–10% via 30–3000 fold clonal expansion in occasional biopsies, due to being cancer drivers. (iii) Cyclobutane pyrimidine dimer (CPD) hyperhotspots attained those frequencies in nearly every biopsy, due to profuse creation plus ~30‐fold clonal expansion. (iv) Neonatal keratinocyte cultures exposed to weeks of low‐dose UVB exposure developed mutations at skin cancer tumor suppressor gene hotspot nt rarely and randomly, as expected. (v) CPD hyperhotspots in gene promoters acquired mutations in days at 1000‐fold higher frequencies. Sun exposure is the strongest risk factor for skin cancer, so quantifiable UV signature mutations at CPD hyperhotspots in normal skin may make it technically feasible to identify individuals in need of monitoring to ensure early detection.
- 22 September 2026
- Published by Wiley in Photochemistry and Photobiology
Open AccessUV signature mutation hyperhotspots as genomic dosimeters
Screening for UV‐sensitive DNA mutation sites as dosimeters for individual sun exposure, using high‐fidelity Duplex Sequencing to reduce false positives and a stringent genome alignment protocol to reduce false negatives, revealed: (i) Sun‐exposed human skin contained UV signature mutations (C → T at a diypyrimidine) >1000‐fold more frequently than unexposed neonatal skin, making these mutations sensitive genomic dosimeters for UV exposure. (ii) Tumor suppressor gene hotspot nucleotides (nt) reached variant allele frequency (VAF) 0.1%–10% via 30–3000 fold clonal expansion in occasional biopsies, due to being cancer drivers. (iii) Cyclobutane pyrimidine dimer (CPD) hyperhotspots attained those frequencies in nearly every biopsy, due to profuse creation plus ~30‐fold clonal expansion. (iv) Neonatal keratinocyte cultures exposed to weeks of low‐dose UVB exposure developed mutations at skin cancer tumor suppressor gene hotspot nt rarely and randomly, as expected. (v) CPD hyperhotspots in gene promoters acquired mutations in days at 1000‐fold higher frequencies. Sun exposure is the strongest risk factor for skin cancer, so quantifiable UV signature mutations at CPD hyperhotspots in normal skin may make it technically feasible to identify individuals in need of monitoring to ensure early detection.
- Open Access
- 18 July 2026
- Published by Elsevier in JAAD International
- Vol. 28, 118-120
Characterization of perineural invasion in basal cell carcinoma
- 18 July 2026
- Published by Elsevier in JAAD International
- Vol. 28, 118-120
Open AccessCharacterization of perineural invasion in basal cell carcinoma
- 10 April 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2635-2639
M10, a bioadhesive UV filter with enhanced and long-lasting photoprotection
- 10 April 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (9) , 2635-2639
M10, a bioadhesive UV filter with enhanced and long-lasting photoprotection
- Open Access
- 16 June 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (5) , 100212
FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
- 16 June 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (5) , 100212
Open AccessFISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
- Open Access
- 9 February 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100189
IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
- 9 February 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (4) , 100189
Open AccessIL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
- 1 October 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (4) , 884-886
Clustered intraepidermal lymphocytes and Langerhans cell microgranulomas are consistently observed in hyperkeratotic palmoplantar eczema compared with palmoplantar psoriasis and mycosis fungoides palmaris et plantaris
- 1 October 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (4) , 884-886
Clustered intraepidermal lymphocytes and Langerhans cell microgranulomas are consistently observed in hyperkeratotic palmoplantar eczema compared with palmoplantar psoriasis and mycosis fungoides palmaris et plantaris
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 217-221
Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 217-221
Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development
- Open Access
- 21 May 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (10) , 2213-2226
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Because our recent research has highlighted the potential roles of single and combination approaches specifically using BCL2, bromodomain and extra-terminal domain (BET), and histone deacetylase (HDAC) inhibition, we aimed to investigate the effects of JAK inhibition on CTCL cells and established CTCL cell lines when paired with these and other targeting agents. Peripheral blood malignant CTCL isolates exhibited differential responses to JAK inhibition, with JAK2 expression levels negatively correlating to 50% inhibitory concentration (IC50) values. Regardless of single-agent sensitivity, JAK inhibition potentiated malignant cell cytotoxicity in combination with BCL2, BET, HDAC, or proteasome inhibition. Combination inhibition of JAK and BCL2 showed the strongest potentiation of CTCL cytotoxicity, driven by both intrinsic and extrinsic apoptosis pathways. JAK inhibition decreased expression of BCL2 in the high-responder samples, suggesting a putative mechanism for this combination activity. These results indicate that JAK inhibition may have major effects on CTCL cells, and that combination strategies using JAK inhibition may allow for more generalized cytotoxic effects against the malignant cells from patients with CTCL. Such preclinical assessments help inform prioritization for combination targeted drug approaches for clinical utilization in the treatment of CTCL.
- 21 May 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (10) , 2213-2226
Open AccessJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T lymphocytes that is more likely to involve the peripheral blood in advanced stages. For such patients with advanced disease, there are few available systemic treatment options, and prognosis remains poor. Exome sequencing studies of CTCL have suggested therapeutic targets, including within the JAK/STAT pathway, but JAK inhibition strategies may be limited by patient-specific mutational status. Because our recent research has highlighted the potential roles of single and combination approaches specifically using BCL2, bromodomain and extra-terminal domain (BET), and histone deacetylase (HDAC) inhibition, we aimed to investigate the effects of JAK inhibition on CTCL cells and established CTCL cell lines when paired with these and other targeting agents. Peripheral blood malignant CTCL isolates exhibited differential responses to JAK inhibition, with JAK2 expression levels negatively correlating to 50% inhibitory concentration (IC50) values. Regardless of single-agent sensitivity, JAK inhibition potentiated malignant cell cytotoxicity in combination with BCL2, BET, HDAC, or proteasome inhibition. Combination inhibition of JAK and BCL2 showed the strongest potentiation of CTCL cytotoxicity, driven by both intrinsic and extrinsic apoptosis pathways. JAK inhibition decreased expression of BCL2 in the high-responder samples, suggesting a putative mechanism for this combination activity. These results indicate that JAK inhibition may have major effects on CTCL cells, and that combination strategies using JAK inhibition may allow for more generalized cytotoxic effects against the malignant cells from patients with CTCL. Such preclinical assessments help inform prioritization for combination targeted drug approaches for clinical utilization in the treatment of CTCL.
- Open Access
- 27 July 2019
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 60 (6) , e477-e490
Associations of Awareness of Age-Related Change With Emotional and Physical Well-being: A Systematic Review and Meta-analysis
Background and Objectives: This systematic review aimed to synthesize and quantify the associations of awareness of age-related change (AARC) with emotional well-being, physical well-being, and cognitive functioning. Research Design and Methods: We conducted a systematic review with a correlational random effects meta-analysis. We included quantitative studies, published from January 1, 2009 to October 3, 2018, exploring associations between AARC and one or more of the following outcomes: emotional well-being, physical well-being, and cognitive functioning. We assessed heterogeneity (I2) and publication bias. Results: We included 12 studies in the review, 9 exploring the association between AARC and emotional well-being and 11 exploring the association between AARC and physical well-being. No study explored the association between AARC and cognitive functioning. Six articles were included in the meta-analysis. We found a moderate association between a higher level of AARC gains and better emotional well-being (r = .33; 95% CI 0.18, 0.47; p <.001; I2 = 76.01) and between a higher level of AARC losses and poorer emotional (r = −.31; 95% CI −0.38, −0.24; p < .001; I2 = 0.00) and physical well-being (r = −.38; 95% CI −0.51, −0.24; p < .001; I2 = 83.48). We found a negligible association between AARC gains and physical well-being (r = .08; 95% CI 0.02, 0.14; p < .122; I2 = 0.00). Studies were of medium to high methodological quality. Discussion and Implications: There is some indication that AARC gains and losses can play a role in emotional well-being and that AARC losses are associated with physical well-being. However, the number of included studies is limited and there was some indication of heterogeneity. PROSPERO Registration: CRD42018111472.
- 27 July 2019
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 60 (6) , e477-e490
Open AccessAssociations of Awareness of Age-Related Change With Emotional and Physical Well-being: A Systematic Review and Meta-analysis
Background and Objectives: This systematic review aimed to synthesize and quantify the associations of awareness of age-related change (AARC) with emotional well-being, physical well-being, and cognitive functioning. Research Design and Methods: We conducted a systematic review with a correlational random effects meta-analysis. We included quantitative studies, published from January 1, 2009 to October 3, 2018, exploring associations between AARC and one or more of the following outcomes: emotional well-being, physical well-being, and cognitive functioning. We assessed heterogeneity (I2) and publication bias. Results: We included 12 studies in the review, 9 exploring the association between AARC and emotional well-being and 11 exploring the association between AARC and physical well-being. No study explored the association between AARC and cognitive functioning. Six articles were included in the meta-analysis. We found a moderate association between a higher level of AARC gains and better emotional well-being (r = .33; 95% CI 0.18, 0.47; p <.001; I2 = 76.01) and between a higher level of AARC losses and poorer emotional (r = −.31; 95% CI −0.38, −0.24; p < .001; I2 = 0.00) and physical well-being (r = −.38; 95% CI −0.51, −0.24; p < .001; I2 = 83.48). We found a negligible association between AARC gains and physical well-being (r = .08; 95% CI 0.02, 0.14; p < .122; I2 = 0.00). Studies were of medium to high methodological quality. Discussion and Implications: There is some indication that AARC gains and losses can play a role in emotional well-being and that AARC losses are associated with physical well-being. However, the number of included studies is limited and there was some indication of heterogeneity. PROSPERO Registration: CRD42018111472.
- 8 July 2019
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (12) , E255-E256
Segmental neurofibromatosis 1 with gonosomal mosaicism
- 8 July 2019
- Published by Wiley in International Journal of Dermatology
- Vol. 58 (12) , E255-E256
Segmental neurofibromatosis 1 with gonosomal mosaicism